B+
Bull case
0%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-06-19 · RankAlpha Sentiment Codex
NUVB
Nuvation BioBNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bull case is that IBTROZI is showing credible early commercial traction, first-line mix is improving, durability data remain strong, and $533.7 million of cash gives Nuvation time to build the launch while advancing safusidenib and other pipeline options [#SEC-8K-2026-05-04].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +4.3.
What can break
Biotech execution risk remains elevated around pivotal-study progress, regulatory timelines, and capital allocation even with a solid current cash balance.
Momentum
45
Value
41
Sentiment
75
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $6.50 · Bull $8.50 · Bear $4.00Analysis 2026-06-19; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-19 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-18
Investment thesis
As of 2026-09-18
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-18. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $13.10
Why
Momentum45 · Δ7d -32.1
Value41 · Δ7d 0.0
Sentiment75 · Δ7d +4.3
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +4.3.
Contradictions & invalidation
- • Biotech execution risk remains elevated around pivotal-study progress, regulatory timelines, and capital allocation even with a solid current cash balance.
- • Commercial uptake depends partly on improving ROS1 testing rates in community oncology, a bottleneck highlighted in the earnings materials.
- • The bear case is that Nuvation is still effectively a single-launch biotech where revenue durability must be proved quarter by quarter, community ROS1 testing remains a bottleneck, and pipeline upside outside IBTROZI still lacks near-dated hard proof points.
Catalyst clock
2026-08-01
IBTROZI launch mix is shifting toward first-line patients
Lead driver: Sentiment · See AI snapshot
Momentum
45
9% active weight
Current posture
7d trendSoftening
Δ7d
-32.1
Δ21d
-7.0
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-0.0
Sentiment
75
62% active weight
Current posture
7d trendImproving
Δ7d
+4.3
Δ21d
+15.7
Why this grade
Composite grade B. Momentum 45.0 / Value 41.2 / Sentiment 75.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-06-19. Scenario method
Most likely
B
Base case
0%
Probability
Target price
$6.50
Analysis reference price unavailable
Analysis 2026-06-19 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$4.00
Analysis reference price unavailable
Analysis 2026-06-19 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$2.28B
Beta
1.53
Shares Out
352.12M
P/E (TTM) · Derived
-10.8
P/S (TTM)
110.10
P/FCF (TTM) · Derived
-18.42
Rev YoY
+555.6%
EPS YoY
+4.0%
Gross Margin
+86.9%
Op Margin
-81.0%
Net Debt
-$316.45M
Current Ratio
8.37
As of 2026-09-18 • Updated nightlySource: Internal modelMethods & Data